Reducing the risk of hepatitis B virus transfusion-transmitted infection by Niederhauser, Christoph
© 2011 Niederhauser, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Journal of Blood Medicine 2011:2 91–102
Journal of Blood Medicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
91
Review
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/JBM.S12899
Reducing the risk of hepatitis B virus  
transfusion-transmitted infection
Christoph Niederhauser
Blood Transfusion Service SRC, Bern, 
Switzerland
Correspondence: Christoph Niederhauser 
Blood Transfusion Service SRC Bern 
Switzerland, Murtenstrasse 133,  
3008 Bern, Switzerland 
Tel +41 31 384 2304 
Fax +41 31 384 3201 
email christoph.niederhauser@bsd-be.ch
Abstract: Before 1970, approximately 6% of multi-transfused recipients acquired a 
  transfusion-transmitted Hepatitis B virus (HBV) infection. The safety improvements since then 
have been tremendous. From a level of a few infections per 1000 donations, the risk today, 
depending on the screening algorithm and additional measurements performed, has decreased 
to around 1:500,000 to 1:1,000,000, an improvement greater than 1000-fold compared to 
50 years ago. This enormous gain in safety has been achieved through many factors, including 
development of increasingly more sensitive Hepatitis B antigen (HBsAg) assays; the adoption in 
some countries of hepatitis B core antibody (anti-HBc) screening; an improved donor selection 
procedure; HBV vaccination programs; and finally the introduction of HBV nucleic acid testing 
(NAT). Because there is a tendency in transfusion medicine to add one safety measure on top 
of another to approach the ultimate goal of zero risks, costs become increasingly a matter of 
debate. It is obvious that any new measure in addition to existing methods or measures will have 
very poor cost effectiveness. Therefore each country needs to perform its own calculation based 
on the country’s own epidemiology, resources, political and public awareness of the risks, in 
order to choose the correct and most cost-efficient measures. Ideally, each country would make 
decisions regarding implementation of additional blood safety measures in the context of both 
the perceived benefit and the allocation of overall health care resources.
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Introduction
Since the milestone introduction of hepatitis B surface antigen (HBsAg) testing in 1969, 
the risk of transfusion-transmitted hepatitis B virus (TTHBV) has steadily decreased, 
thanks to the development of increasingly more sensitive HBsAg assays; the adoption 
in some countries of hepatitis B core antibody (anti-HBc) screening; improved donor 
selection, including nonremunerated intrinsically motivated blood donors; HBV vac-
cination programs; and finally the introduction of hepatitis B virus (HBV) nucleic acid 
testing (NAT) in minipools (MP) or later on as individual (ID) testing.
Several different approaches can be envisaged to reduce the risk of TTHBV . These 
vary according to the prevalence of HBV in a certain region; the extent to which a 
population is already vaccinated against HBV; the local economic situation; the avail-
ability of specific technical equipment; the availability of suitable donors; and the level 
of safety that is requested by the corresponding society. Based on these considerations, 
different algorithms can be foreseen, such as the sole serological approach with 
HBsAg; testing for HBsAg and anti-HBc; serology in combination with a less sensi-
tive NAT (minipools); or on the other hand a highly sensitive ID NAT-only approach. Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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Within these considerations it can be argued whether NAT 
should be dropped and antigen/antibody tests developed for 
more cost-effective screening strategy, or whether HBsAg 
testing could be dropped if an adequate sensitive NAT system 
was adopted. All these possible approaches have advantages 
and disadvantages and will be discussed in the present review. 
In the end, a balance between donor loss, economic reasons, 
required safety, and donor counseling has to be found for 
every country or region and an appropriate algorithm has 
to be defined.
HBsAg testing
A unique feature of the HBV life cycle is the production of 
large amounts of free HBsAg in the form of particles and 
filaments in vast excess to intact DNA-containing virions. 
This phenomenon makes HBsAg a very sensitive and use-
ful marker of HBV infection, and HBsAg testing became 
the first-line screen for HBV. Over the past 40 years, the 
sensitivity of these tests has increased by .2 log10 as the 
technology advanced from crude immunological techniques 
to reverse passive hemagglutination (RPHA) and enzyme 
immunoassays (EIA), including enzyme-linked immunosor-
bent assays (ELISA), and the current assays now employing 
chemiluminescence (CLIA) detection.
There are more than 40 commercially available HBsAg 
assays currently in use around the world. Nevertheless, 
comparative studies have highlighted key differences in 
analytical detection sensitivities for HBsAg from wild type, 
mutant, and specimens of different genotypes among com-
monly used EIAs.1–6 The most sensitive assays detect HBsAg 
levels #0.1 ng/mL, but significantly less sensitive methods 
with detection limits .1 ng/mL still continue to be used 
worldwide. The CLIA sensitivity of 0.08 ng/mL corresponds 
to 102–267 HBV DNA IU/mL as determined by NAT quan-
tification of seroconversion panels, but can only be applied 
to the window period (WP) phase.7,8
Several other deficiencies with HBsAg assays have 
become apparent in recent years. During the 59 day window 
period (45–50 days for most sensitive assays)8–10 for HBV 
infection, HBsAg tests are not sensitive enough. Likewise 
in the early convalescence phase (core window) of HBV 
infection acute phase as well as in chronic HBV infections 
very low levels of HBsAg are often present, which are not 
detected by the routinely used HBsAg assays.11–25
Mutations associated with conformational and hydro-
phobic changes within and outside the immunogenic major 
hydrophilic region (MHR) of the S antigen, the main target for 
capture antibodies in commercial HBsAg assays, often lead 
to reduced synthesis or secretion of HBsAg. Such changes 
may account solely or in conjunction with other factors for 
the failure of immunoassays to detect HBsAg.5,26–31 There 
have been several reports on HBV escape mutants which 
were not detected by HBsAg screening assays.32,33 Blood-
borne transmission of hepatitis B virus continues to occur 
despite implementation of highly sensitive screening tests for 
HBsAg, suggesting these assays are still not sensitive enough 
to prevent all infections.20,24,34 Mutations may occur naturally 
from escaping active or passive immunity or antiviral therapy. 
The prevalence of such mutant strains may reach ∼30% in 
areas of high endemicity following vaccination programs.35,36 
It has been suggested that the presence of anti-HBs in immune 
complexes with the whole virus or HBsAg may hamper the 
binding of HBsAg capture antibodies, thus leading to the 
failure of HBV screening assays.37,38
Anti-HBc testing
Unlike HBsAg, anti-HBc may be present during the chronic 
carrier state and at the end of an acute resolving infection 
where HBsAg may be undetectable. HBV-positive donors 
who are analyzed when they present during these stages 
of the disease can often be identified by either HBV-NAT 
or alternatively by testing for anti-HBc. Anti-HBc testing 
was introduced in several countries (for instance the US, 
Japan, and France) during the 1980s as a surrogate test for 
the so-called non-A, non-B Hepatitis. Testing for anti-HBc 
contributed at that time to the reduction in the number of 
post-transfusion hepatitis B cases in these countries.39,40 
On the other hand, in HBV low-prevalence countries, a large 
proportion of the anti-HBc reactive blood donations may 
be false reactive, due to the lack of specificity of the avail-
able assays.41–43 The reason for this lies within the original 
development of anti-HBc tests. They were devised to test 
patients for suspected viral hepatitis rather than as a donor-
screening assay and thus the sensitivity was increased over 
the specificity.44,45 Studies conducted in three low-prevalence 
countries (Germany, New Zealand, Switzerland) have shown 
that the anti-HBc tests currently used in blood bank settings 
have led to the loss of 2%, 2.5% and 6%–7%, respectively, 
of otherwise eligible donors.46–48 In the US, it is estimated 
that around 500,000 donors were deferred due to isolated 
anti-HBc reactivity and it has been estimated that 65% of 
these deferrals were due to false positive results.42 Several 
studies conducted in Europe and in North America have 
shown that approximately 90% of blood donors positive for 
anti-HBc were also hepatitis B surface antibody (anti-HBs) 
positive, thus suggesting a recovered HBV infection.49 The Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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majority of the remaining 10% of false-reactive anti-HBc 
samples could be explained by a poor assay specificity, 
whereas only a small fraction could be shown to be true 
anti-HBc positive.50,51
Those cases which are solely anti-HBc reactive, the so-
called anti-HBc alone or occult hepatitis B infection (OBI), 
deserve special consideration. There are several possible 
explanations for the anti-HBc alone profile: (i) a late acute 
resolving infection where HBsAg is no longer detectable 
but low-level HBV DNA may persist for a short time; (ii) 
a chronic carrier state, in the presence of anti-HBc, where 
HBsAg levels are below the detection limit of current assays; 
or (iii) HBV infection by a virus carrying mutations resulting 
in low level replication or altered HBsAg epitopes that are 
not detected by some HBsAg assays.31,52–54 These anti-HBc 
alone cases may originate either from recovered infections 
having lost detectable anti-HBs or from late chronic infec-
tions having lost detectable HBsAg.
In some countries with a low level of HBV prevalence, 
deferring all anti-HBc reactive donors was considered 
affordable in terms of potential donations lost (eg, in the 
US, France, and Germany). In Germany a mandatory anti-
HBc test was introduced in October 2006 despite a long 
experience of minipool HBV NAT testing greater than three 
quarters of the German blood supply.55 It was estimated 
that anti-HBc testing would identify most OBI carriers, 
who are responsible for 50%–60% of all HBsAg-negative 
but HBV positive donations. Only 67% of the OBI cases 
were identified by the current high sensitivity 96-member 
minipool NAT tests, whereas 87% of HBsAg negative pre-
seroconverter cases were identified by minipool NAT.55 
The loss of potential donors may be reduced if the anti-HBc 
positive donors are further tested with anti-HBs. Those 
donors who have an anti-HBV titer $100 IU/mL and are 
negative in single donation NAT (detection limit #12 IU/) 
may be used for component preparation. In Japan, a country 
with moderate HBV endemicity, the algorithm for anti-
HBc assays has been modified in order to accept units with 
anti-HBs of .24 (∼200 MIU/mL) even if the anti-HBc titer 
is .25 in conjunction with a negative HBV DNA test.56–58 
Indeed to date no post-transfusion case has been documented 
since using this algorithm.56,59–62 High levels of anti-HBs is 
commonly accepted to be protective against transmission 
but there is at present no agreement on the threshold level 
though 100 IU/L is often cited.63 In many blood centers 
worldwide the introduction of these more sophisticated 
algorithms has not been introduced primarily for economic 
and organizational reasons.
The anti-HBc screening strategy is also not defendable in 
areas of the world where HBV is highly endemic, because an 
unacceptably large percentage of the potential blood donor 
population would be reactive and thus deferred from donation.25 
Once donated, the number of units that would be rejected in 
these countries because of anti-HBc reactivity would be prohibi-
tive to maintaining the blood supply. The two strategies left open 
in these areas are a serological testing algorithm with anti-HBc 
followed by anti-HBs or implementation of highly sensitive 
HBV DNA screening. The latter was adopted in the more 
affluent European Mediterranean countries, Poland, Singapore, 
Hong Kong, Taiwan, Thailand, and South Africa.64–69
In Switzerland, a low prevalence country, the decision 
against the introduction of anti-HBc testing was taken because 
the loss of approximately 2.5% of the otherwise healthy donor 
population was regarded as unacceptable.48 In this study, con-
firmation tests using two alternative anti-HBc assays reduced 
the number of reactive donations by approximately 60%. 
These findings agree with two other studies, where it was 
shown that respectively 32% and 58% of blood donors, 
who were reactive in an initial anti-HBc assay, could not be 
confirmed with two additional assays.51,70 Thus it is difficult 
to evaluate precisely the exact rate of “false” positive reac-
tions of the different available assays. Despite the potential 
loss of false HBV positive donors, anti-HBc testing still has 
a role in screening algorithms as it does reduce the residual 
risk of transfusion-transmitted HBV infection, by deferring 
potential HBV carriers from the donor population. The Paul 
Ehrlich Institute (PEI) reported that seven out of 18 cases of 
proven HBV transmission by blood components reported to 
this institute could have been prevented by anti-HBc testing.71 
There is a strong need for more specific anti-HBc donor 
screening assays. Although in the last 5 years the diagnostic 
industry has improved the specificities of anti-HBc assays, 
there is still room for further improvement. Anti-HBc screen-
ing assays have the potential to exclude the majority of OBIs, 
leaving only rare cases of primary OBI or cases involving 
escape mutants associated with anti-HBs alone. On the other 
hand anti-HBc tests do not detect pre-seroconversion WP 
infections and they are not practicable in areas with anti-HBc 
prevalence .5% where too many donor deferrals would 
negatively impact the blood supply.
NAT testing
The introduction of HBV NAT can overcome safety gaps 
left by HBsAg or anti-HBc testing, as it can potentially 
detect HBV in the very early acute phase, during the late 
chronic phase when very low HBsAg levels are often   present, Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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and can detect HBV escape mutants not recognized by HBsAg 
assays. In the late 1990s, NAT for HBV was introduced in 
several blood transfusion centers across Europe, as well as 
throughout Japan. It was hoped to identify HBV infected units 
during the early phase of acute infection, and in chronic carri-
ers who often have undetectable levels of HBsAg. The initial 
NAT assays mostly analyzed pools of 16 to 96   donations. 
Since 1997 HBV NAT has been introduced as a routine 
screening assay in many countries with quite different HBV 
prevalence levels (1997 in Germany, 1999 in Japan, 2004 
in Spain, 2005 in Poland, Ghana, French Antilles, and La 
Réunion, 2006 in Portugal and 2007 in Switzerland, Slovenia, 
Singapore, Hong Kong, Tawian, and Thailand).64–69,72,73
Blood donors suffering from an acute HBV-DNA positive 
infection and particularly those donating during the WP are 
likely to be highly infectious to transfusion recipients.62,74 
  Different studies have shown that HBV-NAT can signifi-
cantly reduce the WP of HBsAg and this is even more effec-
tive when highly sensitive NAT testing assays are introduced. 
Since the introduction of HBV-NAT a number of potential 
WP donations have been identified.50,56,69,73,75–78
One study comparing seven currently used HBsAg 
tests with commercial HBV NAT in minipools of 16 or 
24 donations (MP-NAT) or ID NAT showed the WP could 
be significantly reduced. In pools the WP was reduced by 
9–11 days, resulting in a WP of 40–50 days. This reduction 
increased to 25–36 days when ID NAT was used leaving an 
effective WP of only 15–34 days.8,79 This study also showed 
that during the early ramp-up phase of infection, HBsAg tests 
detected only 31%–63% of a 100-member HBV seroconver-
sion panel compared with 55%–71% and 82%–99% detected 
by MP and ID NAT, respectively.79
There has been a recent debate over whether HBV NAT 
could eventually replace HBsAg tests. While both are direct 
viral detection assays, HBsAg has a shorter, more variable 
expression period than HBV DNA. A combination of HBV 
NAT and anti-HBc, especially if a highly sensitive NAT is 
implemented, should be preferable to HBsAg and anti-HBc 
screening. On the other hand, large-scale studies still need 
to be conducted to ensure that no incremental risk occurs if 
HBsAg screening is replaced by HBV NAT as a first-line 
screening assay. It is known that approximately 6% of HBsAg 
positive donations are expected to be nonreactive by MP 
NAT and 3% by ID NAT.50,80,81 HBsAg confirmed positive 
but HBV DNA negative donations are found in 2%–16% of 
all donations.69,80,82–84
A long-term persistent and intermittent viremia is not 
infrequent in isolated anti-HBc positive individuals   following 
serological recovery from acute hepatitis B.17,19,30,50,85–88 
  Intermittent low level viremia may persist over very long 
periods of time, as shown in a case study of a blood donor 
who was intermittently polymerase chain reaction (PCR) posi-
tive for HBV DNA (8 to 260 IU/mL or 32–1040 copies) over 
7 years.60 This suggests that clinical and serological resolution 
does not necessarily correspond to eradication of hepatitis B 
virus from infected hosts. Indeed the persistence of HBV DNA 
in serum during the convalescent phase after acute HBV has 
attracted attention as this HBV DNA is potentially infectious 
and thus may play a role in HBV transmission.86
As mentioned, previously anti-HBc positive, HBsAg 
negative blood samples often have persistent very low HBV 
DNA levels ranging from a few to 30 copies/mL.51,73,79,81 
Previous studies have shown that HBV DNA may be still be 
detected in up to 5% of the HBsAg negative, anti-HBc reac-
tive blood donations.89,90 In countries such as China, Japan, 
Saudi Arabia, Ghana, Egypt, and Germany, HBV DNA 
was detectable in 0.3% to 15% of anti-HBc-only units.25,91 
In another study conducted in the US the probability for 
the presence of HBV DNA in anti-HBc positive units lay 
between 1:37,000 and 1:54,000.92
OBIs are mainly found in older donors. Nearly 100% of 
these donors are anti-HBc reactive, and approximately 50% 
also carry anti-HBs suggesting that OBIs occur largely in 
individuals who have recovered from the infection but are 
unable to develop a totally effective immune control.93,94 The 
OBIs are usually characterized by very low plasma HBV 
DNA load (,200 IU/mL). As a consequence of this, the 
occurrence of viremia near the detection limit of the assay 
in these OBI donors and the potential for fluctuating HBV 
viremia in these individuals suggests that such donors, with 
ongoing HBV infection, would only be detected using highly 
sensitive NAT assays.8,59,64,73,79,95–97
Blood which is free of HBsAg but has high anti-HBc titers in 
the absence of anti-HBs, has the potential to transmit HBV .98,99 
Studies published on post-transfusion hepatitis have shown 
that donations reactive for anti-HBc alone or for anti-HBc 
plus anti-HBs have transmitted HBV infection to transfusion 
recipients.11,15,98,100 In one reported case an OBI carrier trans-
mitted HBV to two immunocompetent transfusion recipients 
despite the presence of anti-HBs.101 Apart from shortening the 
WP, NAT screening has uncovered a relatively large number 
of HBsAg-negative occult HBV donors.25,69,73,102
Comparison of MP-NAT to ID NAT
Early studies comparing HBsAg assays and HBV NAT in 
minipools showed that MP NAT was more sensitive than Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
95
Reducing transfusion-transmitted hepatitis B
HBsAg assays,78 whereas others showed that more recently 
developed sensitive HBsAg assays had a comparable sensitiv-
ity to MP-NAT.8 Since HBV has a particularly slow doubling 
time (2.6 days) it has been suggested that this may contribute 
to the greater difference between the sensitive and highly 
sensitive NAT assays.79 Model-derived estimates conducted 
in Europe, Japan, and the US, have generally been predictive 
of the yields of DNA positive, HBsAg negative WP blood 
units. These studies have indicated that the added benefit of 
NAT performed in pooled samples is relatively small in areas 
of low endemicity.
Several reports have estimated the risk of HBV trans-
mission through HBsAg negative and anti-HBc positive 
donations to be approximately 1 in 50,000 donations.51,70,103 
From 3.6 million German blood donations screened by HBV 
NAT in minipools of 96, only four donations were HBV 
DNA positive in minipools and these turned out to be also 
anti-HBc reactive.50 If HBV NAT screening in minipools of 
96 was routinely introduced, probably only one infectious 
donation in 900,000 donations would be detected and poten-
tial transfusion-transmitted infections avoided. However due 
to the low viral loads encountered in chronically infected 
donors, it seems unlikely that NAT in large minipools is 
sensitive enough to detect the majority of potentially infec-
tious donations from anti-HBc positive donors.51 Chronically 
HBV infected donors are more effectively identified when 
highly sensitive ID NAT is used.50
In Japan, HBV DNA screening was introduced in 1999 
using a MP-NAT system comprising 50 donations. Since its 
introduction, more than 500 seronegative but HBV DNA posi-
tive donations were detected. It was still believed, however, 
that units of blood in an early late phase of HBV infection 
with low viral loads were escaping detection by MP-NAT.62,104 
The Japanese thus reduced their pool size from 50 to 20. They 
could demonstrate that several pools which were NAT nega-
tive in 50 donation format were positive in the 20 donation 
format.105,106 Despite this improvement using a 20 MP NAT 
system, the risk of TTHBV could not been completely elimi-
nated. It was believed the format was not sensitive enough 
to pick up extremely low levels of HBV , especially those 
observed in the chronic phase of HBV infections.57,62,104,107
NAT yields
HBV NAT yields for both WP and late-stage infection have 
been determined for several countries in the last decade (eg, the 
US, Germany, Austria, Switzerland, South Africa).46,47,69,73,81,108 
Countries with low HBV endemicity such as Germany, 
  Switzerland, New Zealand, the US, and Canada have reported 
NAT yields ranging from 1:4,000 to 1:730,000,46,47,73,81,108–115 
whereas for countries with moderate endemicity such as 
Poland and some Mediterranean countries, 1:4,000 to 
1:51,987 has been reported,64,65,96,116–118 and countries with high 
endemicity such as Ghana, Hong Kong, India, South Africa 
the figure ranges from 1:186 to 1:5,200.66–69,82,119–123
When comparing NAT yields it is essential to differenti-
ate between calculations based on different screening strate-
gies, such as those using NAT testing and HBsAg testing as 
opposed to NAT testing in combination with HBsAg and 
anti-HBc testing. If NAT was added to HBsAg and anti-HBc 
testing then the NAT yields are clearly less than those derived 
when NAT is added to HBsAg testing alone. In general, those 
areas highly endemic for HBV showed greater NAT yields 
than those with a lower endemicity. Individual sample NAT 
would offer more significant early WP closure and could 
prevent a moderate number of residual HBV transmissions 
not detected by HBsAg assays.124
HBV NAT technologies
Because automation has lagged behind NAT reagent 
development, testing MP of 16–96 samples was initially 
implemented as a temporary solution to allow processing of 
a large number of donor samples. Automated solutions have 
since been developed which promise to provide an efficient 
and cost-effective ID NAT testing strategy. In particular, the 
availability of commercial CE marked and FDA approved 
NAT systems, in multiplex format, detecting HIV , HCV , and 
HBV on automated testing platforms has opened up NAT 
screening for many transfusion centers worldwide. The two 
widely used assays are based on either a polymerase chain 
reaction (PCR) (s201 test system from Roche Diagnostics, 
Basel, Switzerland) or on transcription mediated assays 
(TMA) (Tigris from Novartis Diagnostics, Basel,   Switzerland) 
and have specificities between 99.8% to 100% and very high 
sensitivities ,10 IU mL.8,66 Thus, mass routine screen-
ing, which is efficient and cost-effective, is now feasible. 
Despite their availability many countries have either not yet 
introduced NAT screening or decided which pool size to use. 
It has been suggested that ID-NAT or NAT in small pools 
(#eight donations) will be required to impact HBV blood 
safety significantly.125 In 2009, the Swiss Blood transfusion 
Service Swiss Red Cross declared HBV NAT mandatory 
with a sensitivity of 25 IU/mL per donation.73
The ability of HBV NAT to reduce the WP depends not only 
on the sensitivity of the assay but also on a number of different 
aspects related to how the assay is set up, including the input 
volume used in the assay (100–1000 µL); the dilution   factor Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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  introduced by the pooling process; the use of sample 
  concentration methods; the efficiency of nucleic acid   extraction; 
and the analytical sensitivities of the amplification, and detec-
tion methods.8,56,59,126
Cost effectiveness
The original calculations on the cost-effectiveness of HBV ID-
NAT compared to MP-NAT were rather poor, particularly the 
costs per quality adjusted life year (QUALY).79,127 However 
since the development of the high throughput NAT systems 
the price differences between small MP-NAT and ID-NAT are 
negligible. There is still however a significant difference when 
96 sample pool assays are used. Several medium-prevalence 
countries, such as Poland, prefer to use small MP-NAT of less 
than ten donations or even ID-NAT in order to circumvent 
anti-HBc testing, which is expected to lead to an unaccept-
able loss of blood donors.64 Likewise in Switzerland, a low 
prevalence country, ID-NAT or MP-NAT using six dona-
tions was introduced as an alternative to anti-HBc testing.73 
The additional cost of small MP-NAT or ID-NAT must be 
compared to the cost entailed by anti-HBc testing and to the 
loss of otherwise eligible blood donors and to the marketing 
costs required to replace these deferred donors.
Residual risks
The calculation of residual risk of HBV transmission is 
dependent on a variety of factors. The pre-seroconversion 
WP is important, but so is the theoretical possibility of infec-
tion with immunovariant viruses, as well as the presence of 
donors with an occult carriage of HBV . Reduction of HBV 
residual risk is achieved by the development of more sensi-
tive HBsAg assays; by introducing anti-HBc screening in 
certain communities; by the implementation of the HBV 
NAT technologies; HBV vaccination programs; and an array 
of other measurements.
The impact of more sensitive screening assays on the 
safety of the blood supply is estimated by the extent to which 
the new assay closes the infectious window period. This 
aspect is tested by analyzing HBV seroconversion panels 
and then projecting the effect of closure on the calculated 
residual risk of virus transmission. Using such panels the 
theoretical calculated residual risks for HBV from low 
endemic countries varies between 0.69 and 8.69 per million 
donations.81,111,128–135 In areas of moderate and high   endemicity 
the calculated residual risks ranges from 7.5–15.8 and 
30.6–200, respectively.129,136–138 All the measures introduced 
to reduce the residual risks of transfusion transmission of 
HBV have been helpful.139–141
The risk for HBV is quite difficult to estimate because 
of   limited data for two of the key WP/incidence rate model 
  variables.142 First of all the estimated 59-day infectious WP 
(range: 37–87 days) between HBV acquisition and seroconver-
sion is unfortunately based on only a few transfusion cases, ana-
lyzed with older, less sensitive HBsAg assays.142 Secondly, HBV 
incidence is difficult to estimate, because HBsAg presence and 
persistence are quite variable.8,142 Risk models estimate HBV 
incidence extrapolated from the frequency of HBsAg presence 
in repeat donors. This is dependent on the length of presence 
of HBsAg postinfection and the inter-donation interval. While 
this marker generally correctly identifies incident cases in 
donors who were previously negative, it may underestimate 
the number of new infections, as in the inter-donation period 
recently infected donors may have already lost HBsAg.143 
Finally, risk estimates based on seroconversion to anti-HBc 
will overestimate the true rate of new infections, because of 
the unacceptably high false-anti-HBc reactivity rate often 
observed in blood donors (up to 75% with older assays and up 
to 23% with currently used assays).138,144 Therefore an adjust-
ment factor has been used by some authors to correct for this 
anomaly.142 An additional point which needs to be taken into 
consideration when estimating HBV risk is the large percent-
age of asymptomatic infections which lead to under-reporting, 
both in the general population and probably also in blood 
product recipients. Two investigations conducted in the US 
studied the impact of HBV NAT on residual risk. Kleinman 
and co-workers estimated that by implementing HBV NAT in 
pools of 24, one could potentially identify 39 infectious units 
from the WP and thus prevent 56 cases of TTHBV annually 
in the US.81 Biswas and co-workers estimated that each day 
the WP was reduced translates into 1.4 additional HBV infec-
tions detected per 10 million screened donations. The 18 day 
reduction achieved by ID-NAT compared with HBsAg CLIA 
tests should identify an additional 2–3 HBV cases per million 
donors screened.8 Despite all these limitations, the published 
residual risk estimates seem to have some validity, as they 
tend to parallel the HBV endemicity in the population.
Infectivity
It has been suggested that anti-HBc and HBsAg testing could 
be eventually replaced by a highly sensitive HBV NAT. 
Compared to serological testing, HBV NAT has the additional 
ability to significantly reduce the WP and to detect occult HBV 
carriage. But before this can be done several questions still 
need to be addressed. What should be done with HBsAg or 
anti-HBc positive but HBV DNA negative donations: are they 
  infectious? Blood that is collected during the early WP of HBV Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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infection is highly infectious, but this risk declines as anti-HBs 
develops.74,145,146 In addition the blood transfusion community 
needs to know whether blood components from OBI donations 
are infectious. Clinical observations suggest fewer transmissions 
occur with OBI cases as compared to WP cases. These limited 
transmission rates may be related to the low viral loads generally 
observed in OBIs, the presence of defective variants associated 
with occult carriage, or the presence of anti-HBs. However, more 
recent data suggest that the neutralizing capacity of low anti-
HBs may be inefficient when encountered by exposure to high 
viral loads. Anti-HBc blood units without detectable anti-HBs 
appear moderately infectious except in immunocompromised 
recipients. An immunodeficient elderly patient or patients 
receiving immunosuppressive treatments may be exception-
ally susceptible to infection with lower infectious doses even 
in the presence of anti-HBs. It has been shown that transfusion 
recipients are at an increased risk of a fatal HBV infection due 
to their age and comorbid conditions.34,147
Whether residual risk estimates translate into a true rate of 
infection is still largely unknown since estimates are gener-
ally based on the simplification that all HBV DNA-containing 
donations are infectious. In humans, transmission of HBV 
has been reported from donors in the pre-seroconversion win-
dow period and those donors with an occult HBV infection 
in which the HBV DNA load was below 20 IU/mL.62,94,95,148 
On the other hand transfusions from WP donors and those 
with an OBI were not infectious even though some had viral 
loads between 20 and 500 IU/mL.24,59,62,73,94,148 This lack of 
clear relationship between infectivity and viral load may be 
related to different causes, such as immune factors in the 
recipient; HBV infection phase of the blood donor; the vol-
ume of plasma transfused to the recipient; and the presence 
of HBV neutralizing antibodies.62,149
The situation in HBV vaccinated donors is rather less 
clear. In one study, blood donations that were positive for 
HBV DNA with detectable levels of anti-HBs were infec-
tious in none of the 22 recipients, as compared with a rate 
of infection of 27% among 37 recipients of blood that was 
devoid of anti-HBs.62 Similarly the absence of infectivity 
in the presence of anti-HBs has been observed in other 
studies.60,99,150 Conversely, blood containing HBV DNA with 
low-level anti-HBs (,75 IU/L) may carry a risk of transmis-
sion leading to acute hepatitis.101
Further measures to prevent 
TTHBV
Viral pathogen-reduction processes and vaccina-
tion programs have the potential to reduce TTHBV. 
Unfortunately, while viral reduction processes may be applied 
to platelet concentrates and plasma, the technology has not 
yet been satisfactorily applied to red blood cell components. 
Recently, viral reduction of platelets has been licensed in sev-
eral countries. Published data show reduction rates sufficient 
for naturally occurring viral titers including HBV resulting in 
probably zero residual risk. However, in rare cases HBV can 
reach concentrations in the blood by which reduction proce-
dures cannot be challenged. In addition, pathogen reduction 
procedures are complex, need sophisticated equipment and 
today are not capable of processing large amounts of blood 
products per day on a routine basis. Therefore viral reduc-
tion of red cell concentrates is not yet feasible, thus making 
additional tests inevitable. The cost for pathogen reduction 
procedure lies at present around €170 (Switzerland) for a 
single platelet unit, a cost efficiency that lies far above that of 
current laboratory testing including serology and NAT of any 
kind, even if testing were to be completely discontinued.
Immunization campaigns, if rigorously performed, are 
highly efficient in reducing the risk of TTHBV . However 
it would not be possible to perform such campaigns in all 
countries and it needs a continuance in the long run to ensure 
most of the blood donors have been vaccinated against HBV 
and thus to decrease the prevalence of HBV . The number of 
reports of acute HBV infections have declined in the past years, 
most likely due to better data quality and increasing protection 
against HBV provided by vaccination programs conducted in 
the general population.10 A decrease in HBV infection incidence 
was observed following HBV vaccine implementation in 
many countries with moderate or high HBV endemicity.151–153 
  However it may take many years or even decades to decrease 
the prevalence of HBV among blood donors, as the vaccine is at 
present usually only given to adolescents, newborns, and people 
at risk of exposure to HBV in their profession. Vaccination on the 
other hand may favor the development of escape mutants. Anti-
HBs in vaccinated people become undetectable over time and 
they are susceptible to HBV infection. In addition, up to 5% 
of vaccinated individuals do not respond.115,154 These may pass 
undetected by HBsAg or HBV DNA testing. A study performed 
in the US screened 3,694,585 donations for HBsAg, anti-HBc, 
and HBV NAT. NAT testing was performed in individual 
donations for 576,940 donations (10.4 IU/mL) and 3,117,918 
in MP of 16 donations. In total 426 donors were confirmed 
HBV positive. Nine NAT-only cases were found, including 
six samples from donors who had previously been vaccinated 
against HBV . These six donors had a brief transient course of 
infection with no evidence of disease and very low or absent 
expression of HBsA.115 The viral loads of the six HBV NAT Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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cases varied from 11 to 86 IU/mL. With highly sensitive NAT 
systems it should be feasible to detect most of these vaccinated 
but HBV DNA positive donors. HBV A2 is the parent strain 
for vaccination. All five vaccinated donors harbored all non-A2 
HBV strains. It appears the vaccination is less effective against 
non-A2 HBV strains. In all vaccinated cases, during re-infection 
the ALAT levels were not elevated.
In another study, blood donations that were positive 
for HBV DNA with detectable loads of anti-HBs were not 
infectious in any of 22 recipients, as compared with the rate 
of infection of 27% among 37 recipients of blood that was 
devoid of anti-HBs.62 Similarly the absence of infectivity 
in the presence of anti-HBs has been observed in other 
studies.60,61,99,150,155 Conversely, blood containing HBV DNA 
with low-level anti-HBs (#75 IU/mL) may carry a risk of 
transmission leading to acute hepatitis B.101 All in all, the 
significance of the potential for TTHBV from vaccinated or 
naturally infected anti-HBs positive donors is not yet clear.
Summary
Before 1970, approximately 6% of multi-transfused recipi-
ents acquired TTHBV . This risk has declined over the past 
40 years, yet HBV transmission is still the most frequent 
transfusion-transmitted viral infection.156 Subsequent to the 
implementation of HBsAg screening and the elimination 
of most paid units, but prior to anti-HBc screening, it was 
shown that 0.3% to 1.7% of transfusion recipients developed 
HBV .157 The safety improvements made over the last 40 years 
have been tremendous. From the several infections per 1000 
donations in the past, today the risk lies between 1:500,000 
and 1:1,000,000 depending on the screening algorithm and 
additional measurements performed, which is an improve-
ment in excess of 1000-fold compared to 40 years ago.
There is a tendency in transfusion medicine to add one 
safety measure on top of another to approach the ultimate goal 
of zero risk. However the incurring costs become increas-
ingly a matter of debate and it is now obvious that any new 
measure added to the existing methods will have very poor 
cost effectiveness. Therefore each country needs to perform 
its own calculation based on local epidemiology, resources, 
and political and public awareness of the risks, in order to 
take the right and most cost-efficient measures. Ideally, each 
country would make decisions regarding implementation 
of additional blood safety measures in the context of both 
the perceived benefit and the allocation of overall health 
care resources. While the cost of NAT will vary depending 
on the infrastructure in place and the volume of units to be 
tested, there are three important factors that could impact 
a   country’s decision on whether or not to implement HBV 
NAT: firstly the prevalence of HBV in the country, which 
directly impacts the risk of TTHBV; secondly, the current 
use or appropriateness of the anti-HBc screening assays, 
along with an estimation of the fraction of HBV NAT-yield 
that would come from WP or late infections; and thirdly 
the decision to undertake pooled or individual NAT testing. 
Countries with a high prevalence have the highest risk of 
TTHBV and probably gain the most from HBV NAT. For 
low-prevalence countries that have already adopted HIV and 
HCV NAT for blood screening, the addition of HBV NAT, 
especially with the current commercially available multiplex 
NAT systems, requires no additional effort or cost.
Different approaches could be feasible. For instance, 
serology testing with HBsAg and anti-HBc could be envis-
aged; or serology in combination with NAT in MP (less 
sensitive NAT); or highly sensitive NAT only. Should NAT 
be suspended and antigen/antibody tests further developed 
for more cost-effective screening? Or would it be possible to 
replace serology if a highly sensitive HBV NAT system was 
in place? A combination of HBV NAT and anti-HBc, espe-
cially if a highly sensitive NAT is implemented, would be 
preferable to HBsAg and anti-HBc screening.   Nevertheless, 
large-scale infectivity studies still need to be done to ensure 
no incremental risk occurs, if HBsAg or anti-HBc screening 
were to be discarded. Vaccination programs started must be 
continued and when possible extended. In addition to the 
safety of blood products these vaccination programs also 
bring benefit to the general population.
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